Meeting
2011 ASCO Annual Meeting
A phase II trial evaluating efficacy of neo-/adjuvant EIA CTX, surgery, and radiation therapy in high-risk soft tissue sarcoma.
Authors
T. Schmitt
Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
T. Schmitt , B. Kasper , M. Bischof , B. Lehner , S. Dietrich , A. Dimitrakopoulou-Strauss , L. G. Strauss , G. Mechtersheimer , P. Wuchter , A. D. Ho , G. Egerer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
2004-002501-72
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10076)
Abstract #
10076
Poster Bd #
49C
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.
First Author: Danielle Klingberg
Poster
2021 ASCO Annual Meeting
The impact of multimodality therapies in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program (TSP) experience.
First Author: Olga Vornicova
Poster
2021 ASCO Annual Meeting
The SINTART 1 study: A phase II trial of induction chemotherapy (IC), surgery, photon-, proton-and carbon ion-based radiotherapy (RT) integration in locally advanced operable sinonasal epithelial tumors patients (pts).
First Author: Carlo Resteghini
Poster
2016 ASCO Annual Meeting
The impact of multimodality therapy in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program Experience.
First Author: Samer Salah